home | publications

2009 PUBLICATIONS

1. COMPARE Registry Steering Committee.: The COMPARE Registry: Design and Baseline Patterns of Care for Men With Biochemical Failure After Definitive Treatment of Localized Prostate Cancer.
Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT.
Urology. 2009 Jul 7. [Epub ahead of print] (2009).
Abstract

2. The Center for Prostate Disease Research (CPDR): A multi-disciplinary approach to translational research.
Brassell SA, Dobi A, Srivastava S, McLeod DG.
Urologic Oncology: Seminars and Original Investigations, in press (2009).
Abstract

3. Periostin (POSTN): Novel stromal marker of prostate cancer progression- Comparative analysis of gene expression signatures of 3-D culture and clinical samples.
Tsunoda T, Furusato B, Tyson DR, Ravulapalli S, Dobi A, Srivastava S, Naito S, Sesterhenn IA, Ornstein DK
The Prostate, May 28. [Epub ahead of print] (2009).

4. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.
BJU Int. 2009 Aug;104(3):310-4. [Epub ahead of print] (2009).
Abstract

5. Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells reflects TMPRSS2-ERG Fusion Status.
Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sestrehenn IA, McLeod DG. Srivastava S, Petrovics G.
Prostate Cancer and Prostatic diseases, Jul 14. [Epub ahead of print] (2009).
Abstract

6. Longterm Follow up Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrencein High-Risk Prostate Cancer Patients.
Jeremy D Gates, MD, Mark G Carmichael, MD, Linda C Benavides, MD, Jarrod P Holmes, MD,Matthew T Hueman, MD, Michael M Woll, MD, Constantine G Ioannides, PhD, Craig H Robson, MD,David G McLeod, MD, Sathibalan Ponniah, MD, George E Peoples, MD
J am Col Surg, 208 193-201 (2009).
Abstract

7. Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression.
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML
Cancer Res, 69(13):5568-74, 2009.
Abstract

8. Clinicopathological Behavior of Single Focus Prostate Adenocarcinoma.
Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA
J Urol, 182(6):2689-94, 2009.
Abstract

9. Advances made in the Treatment of Testicular Cancer in the U.S. Military: 1946 to the Present.
Hawksworth DJ, McLeod DG, Brassell SA
Urol Oncol, 27(5):553-7. Review, 2009.
Abstract